These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23252907)

  • 1. The role of complement in experimental autoimmune myasthenia gravis.
    Kusner LL; Kaminski HJ
    Ann N Y Acad Sci; 2012 Dec; 1274(1):127-32. PubMed ID: 23252907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis.
    Soltys J; Halperin JA; Xuebin Q
    J Neuroimmunol; 2012 Mar; 244(1-2):63-9. PubMed ID: 22325826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.
    Kaminski HJ; Li Z; Richmonds C; Lin F; Medof ME
    Exp Neurol; 2004 Oct; 189(2):333-42. PubMed ID: 15380483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement associated pathogenic mechanisms in myasthenia gravis.
    Tüzün E; Christadoss P
    Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell surface complement regulators moderate experimental myasthenia gravis pathology.
    Kusner LL; Halperin JA; Kaminski HJ
    Muscle Nerve; 2013 Jan; 47(1):33-40. PubMed ID: 23042232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel complement inhibitor limits severity of experimentally myasthenia gravis.
    Soltys J; Kusner LL; Young A; Richmonds C; Hatala D; Gong B; Shanmugavel V; Kaminski HJ
    Ann Neurol; 2009 Jan; 65(1):67-75. PubMed ID: 19194881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.
    Tüzün E; Scott BG; Goluszko E; Higgs S; Christadoss P
    J Immunol; 2003 Oct; 171(7):3847-54. PubMed ID: 14500686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
    Baggi F; Antozzi C; Toscani C; Cordiglieri C
    Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenia gravis: the role of complement at the neuromuscular junction.
    Howard JF
    Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental autoimmune myasthenia gravis in the mouse.
    Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
    Curr Protoc Immunol; 2013; Chapter 15():Unit 15.8.. PubMed ID: 23392639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia.
    Kaminski HJ; Kusner LL; Richmonds C; Medof ME; Lin F
    Exp Neurol; 2006 Dec; 202(2):287-93. PubMed ID: 16859686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.
    Küçükerden M; Huda R; Tüzün E; Yılmaz A; Skriapa L; Trakas N; Strait RT; Finkelman FD; Kabadayı S; Zisimopoulou P; Tzartos S; Christadoss P
    J Neuroimmunol; 2016 Jun; 295-296():84-92. PubMed ID: 27235354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis.
    Tüzün E; Saini SS; Ghosh S; Rowin J; Meriggioli MN; Christadoss P
    Neuromuscul Disord; 2006 Feb; 16(2):137-43. PubMed ID: 16427283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
    Tüzün E; Saini SS; Morgan BP; Christadoss P
    J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis.
    Tüzün E; Saini SS; Yang H; Alagappan D; Higgs S; Christadoss P
    J Neuroimmunol; 2006 May; 174(1-2):157-67. PubMed ID: 16527362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis.
    Christadoss P; Tüzün E; Li J; Saini SS; Yang H
    Ann N Y Acad Sci; 2008; 1132():210-9. PubMed ID: 18567870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Acetylcholine Receptor Immunization Induces a Robust Model of Experimental Autoimmune Myasthenia Gravis in Mice.
    Theissen L; Schroeter CB; Huntemann N; Räuber S; Dobelmann V; Cengiz D; Herrmann A; Koch-Hölsken K; Gerdes N; Hu H; Mourikis P; Polzin A; Kelm M; Hartung HP; Meuth SG; Nelke C; Ruck T
    Cells; 2024 Mar; 13(6):. PubMed ID: 38534352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice.
    Morgan BP; Chamberlain-Banoub J; Neal JW; Song W; Mizuno M; Harris CL
    Clin Exp Immunol; 2006 Nov; 146(2):294-302. PubMed ID: 17034582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting classical complement pathway to treat complement mediated autoimmune diseases.
    Tüzün E; Li J; Saini SS; Yang H; Christadoss P
    Adv Exp Med Biol; 2008; 632():265-72. PubMed ID: 19025128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental autoimmune myasthenia gravis in the mouse.
    Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
    Curr Protoc Immunol; 2011 Nov; Chapter 15():Unit 15.23. PubMed ID: 22048803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.